Strategic Global Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,996
| Closed | -$245K | – | 148 |
|
|
2024
Q3 | $245K | Buy |
+5,996
| New | +$245K | 0.05% | 134 |
|
|
2023
Q3 | – | Sell |
-15,125
| Closed | -$539K | – | 157 |
|
|
2023
Q2 | $539K | Sell |
15,125
-280
| -2% | -$10K | 0.08% | 122 |
|
|
2023
Q1 | $548K | Sell |
15,405
-243
| -2% | -$8.5K | 0.09% | 117 |
|
|
2022
Q4 | $550K | Buy |
15,648
+3,701
| +31% | +$123K | 0.09% | 112 |
|
|
2022
Q3 | $352K | Buy |
11,947
+7,620
| +176% | +$289K | 0.06% | 123 |
|
|
2022
Q2 | $235K | Sell |
4,327
-7,243
| -63% | -$400K | 0.04% | 139 |
|
|
2022
Q1 | $630K | Buy |
11,570
+3,966
| +52% | +$215K | 0.09% | 109 |
|
|
2021
Q4 | $1.88M | Buy |
+7,604
| New | +$396K | 0.24% | 104 |
|
|
2021
Q3 | – | Sell |
-31,448
| Closed | -$1.56M | – | 145 |
|
|
2021
Q2 | $1.56M | Buy |
31,448
+176
| +0.6% | +$8.46K | 0.28% | 114 |
|
|
2021
Q1 | $1.4M | Buy |
31,272
+90
| +0.3% | +$4.08K | 0.25% | 111 |
|
|
2020
Q4 | $1.43M | Sell |
31,182
-11,509
| -27% | -$529K | 0.25% | 113 |
|
|
2020
Q3 | $2.01M | Buy |
42,691
+8,158
| +24% | +$409K | 0.38% | 73 |
|
|
2020
Q2 | $1.76M | Buy |
34,533
+15,999
| +86% | +$821K | 0.38% | 71 |
|
|
2020
Q1 | $878K | Sell |
18,534
-198
| -1% | -$10.6K | 0.23% | 98 |
|
|
2019
Q4 | $1.1M | Buy |
18,732
+61
| +0.3% | +$3.39K | 0.23% | 101 |
|
|
2019
Q3 | $996K | Buy |
18,671
+81
| +0.4% | +$4.17K | 0.22% | 104 |
|
|
2019
Q2 | $930K | Buy |
18,590
+121
| +0.7% | +$6.07K | 0.2% | 110 |
|
|
2019
Q1 | $965K | Buy |
18,469
+12,889
| +231% | +$644K | 0.2% | 106 |
|
|
2018
Q4 | $267K | Buy |
5,580
+148
| +3% | +$7.29K | 0.1% | 143 |
|
|
2018
Q3 | $273K | Sell |
5,432
-4,527
| -45% | -$230K | 0.08% | 168 |
|
|
2018
Q2 | $486K | Hold |
9,959
| – | – | 0.12% | 121 |
|
|
2018
Q1 | $486K | Buy |
9,959
+194
| +2% | +$9.04K | 0.17% | 111 |
|
|
2017
Q4 | $433K | Hold |
9,765
| – | – | 0.14% | 115 |
|
|
2017
Q3 | $496K | Buy |
9,765
+22
| +0.2% | +$1.12K | 0.19% | 106 |
|
|
2017
Q2 | $525K | Buy |
9,743
+60
| +0.6% | +$3.2K | 0.19% | 96 |
|
|
2017
Q1 | $510K | Buy |
9,683
+601
| +7% | +$30.5K | 0.18% | 102 |
|
|
2016
Q4 | $437K | Buy |
9,082
+2,480
| +38% | +$123K | 0.16% | 115 |
|
|
2016
Q3 | $358K | Buy |
6,602
+82
| +1% | +$4.5K | 0.13% | 125 |
|
|
2016
Q2 | $353K | Hold |
6,520
| – | – | 0.13% | 123 |
|
|
2016
Q1 | $330K | Buy |
+6,520
| New | +$325K | 0.14% | 120 |
|
|
2015
Q3 | – | Sell |
-7,194
| Closed | -$375K | – | 136 |
|
|
2015
Q2 | $375K | Buy |
7,194
+3,011
| +72% | +$170K | 0.22% | 101 |
|
|
2015
Q1 | $241K | Hold |
4,183
| – | – | 0.18% | 117 |
|
|
2014
Q4 | $223K | Buy |
+4,183
| New | +$234K | 0.2% | 125 |
|
Other funds holding GSK
JEST
Strategic Global Advisors's GSK Position: Q4 2024 in Review
Strategic Global Advisors sold out of GSK (GSK) in Q4 2024, closing a stake of 5,996 shares — an estimated $245K sold.
Strategic Global Advisors first reported a position in GSK in Q4 2014 and held it in 33 quarters. The position peaked at $2.01M in Q3 2020. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.
- Strategic Global Advisors reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
- Strategic Global Advisors sold 5,996 GSK shares in Q4 2024, an estimated $245K.
- Strategic Global Advisors first reported a position in GSK in Q4 2014 and held it in 33 quarters.
- Strategic Global Advisors's GSK position peaked at $2.01M in Q3 2020.
- 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.
Based on Strategic Global Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.